What Does the Research Say About Lion’s Mane and Alzheimer’s Disease?

12 hours ago
5 min read

The most advanced human clinical trial on lion's mane and Alzheimer's disease — a 49-week double-blind placebo-controlled study of 49 patients with mild Alzheimer's disease — found significantly less cognitive deterioration in the treatment group compared to placebo, alongside measurably higher plasma Nerve Growth Factor levels. Preclinical research consistently demonstrates reductions in amyloid-beta plaques, phosphorylated tau, and improvements in spatial memory and learning. Lion's mane is not an approved treatment for Alzheimer's disease. It is, however, the most scientifically documented dietary candidate for supporting the neurobiological processes that degenerate in it.

The biology of Alzheimer's disease and where lion's mane fits

Alzheimer's disease is defined by two structural hallmarks: amyloid-beta plaques, which accumulate between neurons and disrupt signaling, and neurofibrillary tangles formed from phosphorylated tau protein, which accumulate inside neurons and compromise their internal transport systems. Both processes are causally associated with the death of cholinergic neurons in the basal forebrain — the population of cells whose degeneration produces the memory impairment that characterizes early Alzheimer's disease.

Nerve Growth Factor is the protein that supports the survival and maintenance of these cholinergic neurons. In Alzheimer's disease, NGF processing is disrupted — a phenomenon called dysregulated neurotrophin signaling — and this disruption precedes and contributes to cholinergic neuron death. Restoring or supporting NGF activity is therefore a logical therapeutic target, and one that has been pursued intensively in pharmaceutical research for decades without a clinically viable drug emerging.

Lion's mane enters this picture through its erinacines and hericenones — compounds that stimulate endogenous NGF synthesis inside the brain through the same mechanism documented in cognitive function research, but applied here to the specific cholinergic population that Alzheimer's destroys. The additional anti-inflammatory and antioxidant mechanisms reduce the neuroinflammatory load that accelerates amyloid deposition and tau phosphorylation. The result is a functional food with multiple convergent mechanisms relevant to Alzheimer's pathology.

The preclinical evidence

Multiple preclinical studies using established Alzheimer's mouse models have examined the effect of lion's mane supplementation on the primary pathological features of the disease. The findings are consistent: lion's mane reduces amyloid-beta plaque accumulation, lowers phosphorylated tau protein levels, increases neurogenesis in the hippocampus, reduces astroglial and microglial activation (markers of neuroinflammation), and improves spatial memory and learning performance on validated behavioral tests.

These effects have been documented across multiple research groups using different mouse models and different preparations of lion's mane — including both erinacine A and erinacine S, as well as ethanol extracts of the fruiting body. The consistency across independent preclinical studies using distinct experimental approaches substantially strengthens the biological case for lion's mane in Alzheimer's research beyond what any single study could establish.

Treatment of Alzheimer's mouse models with Hericium erinaceus preparations including erinacine A and erinacine S reduced amyloid-beta plaque accumulation, lowered phosphorylated tau protein levels, reduced astroglial and microglial activation, increased hippocampal neurogenesis, and improved spatial memory and learning performance on validated behavioral tests. These results were consistent across multiple independent studies using distinct experimental approaches. Chen et al., 2016; Tzeng et al., 2018, as reviewed in Contato and Conte-Junior, Nutrients, 2025.

The human clinical trial

The most significant human clinical trial on lion's mane and Alzheimer's disease was a 49-week double-blind, placebo-controlled pilot study conducted in Taiwan and published in Frontiers in Aging Neuroscience in 2020. Forty-nine patients with mild Alzheimer's disease were randomized to receive either erinacine A-enriched lion's mane mycelium (three capsules daily, each containing 350 mg with 5 mg/g erinacine A) or placebo.

At the end of 49 weeks, the treatment group showed significantly less deterioration on the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) than the placebo group. Brain imaging revealed measurable differences in the inferior frontal gyrus, a region involved in language and executive function. Most importantly, plasma NGF levels were measurably higher in the treatment group than in the placebo group — providing direct human biomarker confirmation that the proposed mechanism, oral lion's mane consumption raising brain NGF, operates as the preclinical research predicted.

A double-blind, placebo-controlled pilot trial of 49 patients with mild Alzheimer's disease found that 49 weeks of erinacine A-enriched Hericium erinaceus mycelia supplementation resulted in significantly less cognitive deterioration on the ADAS-Cog scale, measurable brain imaging differences in the inferior frontal gyrus, and higher plasma NGF levels in the treatment group compared to placebo. The trial was well-tolerated; four subjects withdrew due to mild gastrointestinal symptoms. Li et al., Frontiers in Aging Neuroscience, 2020.

The broader neurodegeneration research context

The 2009 Mori trial in adults with mild cognitive impairment — the clinical stage immediately preceding Alzheimer's diagnosis — adds an important dimension to the research picture. Mild cognitive impairment is the window in which dietary interventions have the greatest theoretical potential to slow progression: neurodegeneration has begun but significant cognitive reserve remains. The progressive cognitive improvement followed by post-discontinuation decline in the Mori trial is consistent with lion's mane providing ongoing NGF support that sustains function as long as it is maintained.

In a double-blind, parallel-group, placebo-controlled trial of 30 subjects aged 50–80 with mild cognitive impairment, 16 weeks of Hericium erinaceus supplementation produced significantly higher cognitive function scores at weeks 8, 12, and 16 compared to placebo, with scores declining significantly after discontinuation. The progressive improvement and washout pattern is consistent with ongoing NGF-mediated neuronal support. Mori et al., Phytotherapy Research, 2009.

A 2025 narrative review confirmed that the neuroprotective properties of Hericium erinaceus, including NGF stimulation, anti-inflammatory activity, and antioxidant effects, are mechanistically relevant to Alzheimer's pathology and supported by both preclinical and early clinical evidence. The review identified large-scale, long-term clinical trials as the critical next step for clinical validation. Contato and Conte-Junior, Nutrients, 2025.

A systematic review of 26 human and preclinical studies confirmed the neuroprotective effects of Hericium erinaceus including anti-tumor, antioxidant, and anti-inflammatory mechanisms, and identified the mushroom as a candidate for further investigation as a functional food and adjunct therapeutic agent in neurodegenerative disease contexts. Menon et al., Frontiers in Nutrition, 2025.

What the evidence shows and what it does not

Lion's mane is not an approved treatment for Alzheimer's disease. The 2020 Li trial, while rigorous in design, was a pilot study with 49 participants. It establishes proof of concept and demonstrates biomarker confirmation of mechanism, but it does not constitute sufficient evidence for clinical recommendations. Large-scale, multi-center randomized controlled trials — the standard required for therapeutic claims — have not yet been completed.

What the evidence does show is a consistent mechanistic and clinical signal that is more developed than for any other dietary intervention in the Alzheimer's space. The mechanism is well-characterized at the molecular level. The preclinical evidence is consistent across multiple independent research groups. The human pilot trial confirmed the mechanism operates in humans and showed a significant effect on cognitive decline. That is a meaningful foundation, appropriately understood as promising early-stage clinical evidence rather than established therapeutic efficacy.

What this means for your plate

The dietary pattern associated with reduced neurodegeneration risk in population research is characterized by consistent, regular inclusion of foods that support neurotrophin signaling and reduce neuroinflammation. Lion's mane is the only food with direct, mechanistically characterized evidence for NGF stimulation in the human central nervous system. Including it regularly — two to three times per week — places you in a dietary pattern consistent with the intervention doses used in the clinical research.

The earlier in life this pattern is established, the greater the theoretical benefit: neurodegeneration is a decades-long process, and the window for dietary intervention is widest before significant neuronal loss has occurred. Lion's mane for brain health is not an emergency intervention for a diagnosed condition. It is a preventive dietary practice grounded in the best available mechanistic and clinical evidence.

Continue exploring the Lion's Mane science

What Are the Proven Health Benefits of Lion's Mane Mushroom?
Can Lion's Mane Improve Memory and Focus? What the Clinical Trials Show
How Lion's Mane Stimulates Nerve Growth Factor — and Why That Matters
Does Lion's Mane Help with Anxiety and Depression? A Review of the Clinical Evidence